Skip to main content
SpringerLink
Log in

Alirocumab

Elevated LDL cholesterol due to alirocumab reduction and worsening of allergic rhinitis: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Piqueras Ruiz S, et al. Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?. Clinica e Investigacion en Arteriosclerosis 32: 30-32, No. 1, Jan-Feb 2020. Available from: URL: http://doi.org/10.1016/j.arteri.2019.04.003 [Spanish; summarised from a translation]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alirocumab. Reactions Weekly 1834, 18 (2020). https://doi.org/10.1007/s40278-020-87210-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-87210-8

Search

Navigation